BioSpace
Facts
- HQ
- United States
- Sectors
- Media, Biopharma, Healthcare
BrainChild Bio raises $119M Series A to fund pivotal Phase 2 of CAR T BCB-276 for deadly pediatric DIPG
BrainChild Bio raised $119 million in a Series A to advance CAR T therapies for pediatric central nervous system cancers, funding a pivotal Phase 2 trial of lead asset BCB-276 for diffuse intrinsic pontine glioma (DIPG) and preclinical work on BCB-214.
InduPro Raises $77M Series B Led by The Column Group and Doses First Patient in Phase 1 Trial of IDP-001
InduPro closed a $77 million Series B financing led by The Column Group and dosed the first patient in a Phase 1 trial of IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumor-associated proximity antigen for advanced squamous NSCLC and other solid tumors.